Protagen specializes in supporting the pharma and biotech industries in their quest to develop effective immunotherapies, via collaborative projects with its strategic partners. At the forefront of immuno-profiling, and the discovery of novel autoantibodies as effective biomarkers for immuno-oncology, Protagen is helping to overcome the barriers to successful cancer treatment.
Using its proprietary biomarker identification platform (SeroTag®), and with a pipeline of stratification arrays based on biomarker panels (NavigAID) to screen patient serum specimens currently under development, Protagen is able to detect novel autoantibody signatures to provide:
Improved response prediction and patient monitoring via autoantibody profiling
The early detection of immune-related adverse events (irAEs)
Download our new whitepaper to learn more about how biomarker discovery can enhance cancer immunotherapy development.